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Abstract
Background: The principal role of Toll-like receptor 4 (TLR4) is the induction of immune responses to
lipopolysaccharides. Previously, mice deficient in the TLR4 gene exhibited up-regulation of the NADPH oxidase
system in the lungs. This resulted in increased oxidant generation and elastolytic activity, which led to pulmonary
emphysema. It was suggested that TLR4 might maintain constitutive lung integrity by modulating oxidant
generation. We investigated whether single nucleotide polymorphisms (SNPs) in the TLR4 gene were associated
with the emphysema phenotype in Japanese subjects with chronic obstructive pulmonary disease (COPD).
Results: Seven SNPs in the TLR4 gene (rs10759930, rs1927914, rs12377632, rs2149356, rs11536889, rs7037117, and
rs7045953) were genotyped with allelic discrimination assays. The frequencies of SNPs were compared between 106
patients with the emphysema phenotype of COPD and 137 healthy smokers. We found that the positivity of the
individuals with the major G allele of rs11536889 was significantly less in the emphysema group than the control
group (p = 0.019). The frequencies of the minor C allele and the distribution of the CC genotype as well as the
frequency of the major haplotype that carried the minor C allele of rs11536889 were all significantly higher in the
emphysema group than the control group (p = 0.0083, 0.019, and 0.004, respectively). Furthermore, the strength of
the association of the CC genotype with the emphysema phenotype was in an odds ratio of 2.60 with 95%
confidence intervals from 1.17 to 5.78. However, these significances were not apparent after adjust for age and
smoking history by logistic regression. No associations were observed between the rs11536889 and the low
attenuation area score, the forced expiratory volume, and the carbon monoxide diffusion capacity in the
emphysema group.
Conclusions: The minor C allele of the rs11536889 SNP in the TLR4 gene is likely associated with the risk of
developing emphysema in the Japanese population.
Background
Chronic obstructive pulmonary disease (COPD) is a
major global health problem that causes 64 million
patients with COPD worldwide in 2004 and more than
3 million deaths in 2005 [1]. COPD is predicted to
become the third most common cause of death and the
fifth most common cause of disability in the world by
2020 [2]. The inflammation, extracellular matrix synth-
esis, oxidative stress and apoptosis are the major patho-
physiological pathways in the mechanisms of COPD [3].
Recently, an animal model of autoimmune emphysema
showed that CD4+ cell-dependent mechanisms were
sufficient to trigger the development of emphysema,
suggesting that alveolar septal cell destruction might
result from immune mechanism [4]. The development
of COPD is known to be influenced by multiple genetic
factors [5]. A coding variant in surfactant protein B
(SFTPB Thr131Ile) and the (GT)31 allele of the heme
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were evidenced to be associated with COPD in both the
family-based study and case-control study [6]. In addi-
tion, TNF-a-308-1 and TNF-a-308-2 alleles, IL-13 pro-
moter polymorphisms, metalloproteinase (TIMP)-2
polymorphisms, and b2-adrenoceptor Gly16 polymorph-
ism were proved to be significantly associated with the
presence of smoking-related COPD [7]. We also demon-
strated that the transforming growth factor beta 1 gene
polymorphisms were associated with emphysema pheno-
type of COPD in Japanese [8]. Recently, genome-wide
association study identified bicaudal D homolog 1
(BICD1) as a susceptibility gene for emphysema [9].
However, few evidences have shown that genes involved
with innate immune system are associated with emphy-
sema or COPD.
The principal role of Toll-like receptors (TLRs) is the
induction of immune responses. TLRs activate both
innate and adaptive immune responses; they regulate
the immediate response to pathogens and antigen pre-
sentation to the adaptive system [10,11]. Among the
TLR family members, TLR4 is activated by bacterial
lipopolysaccharides (LPS) [12]. LPS is a glycolipid com-
ponent of Gram-negative bacteria cell walls; it is present
in airborne particles, like tobacco smoke [13]. Recent
evidence has demonstrated that mice deficient in the
TLR4 gene developed pulmonary emphysema [14]. In
that study, TLR4 knock out mice exhibited upregulation
of a novel NADPH oxidase system in lungs and
endothelial cells; this resulted in increased oxidant gen-
eration and elastolytic activity. However, various media-
tors of inflammation, including IL-1b,T N F - a,I L - 6 ,I L -
13, IFN-g, and VEGF, were not differentially expressed.
It is thought that TLR4 might maintain constitutive
lung integrity by modulating oxidant generation. In
a n o t h e rs t u d y ,w h e nT L R 4t r a n s g e n i cm i c ew e r e
exposed to hyperoxia, reduced apoptosis was observed
in alveolar type I and II epithelial cells and alveolar
macrophages. In addition, antiapoptotic molecules, like
heme oxigenase-1, were up-regulated [15]. Those results
suggested that TLR4 may function to protect against the
development of emphysema through defending the oxi-
dative stress and apoptosis.
The TLR4 gene is located on chromosome 9q32-33; it
spans approximately 13 kb and contains three exons
that encode a 222-amino acid protein. Single nucleotide
polymorphisms (SNPs) in the TLR4 gene have been
reported to be associated with endotoxin hyporespon-
siveness and gram-negative infections [16-18]. TLR4
SNPs have been shown to affect the risks of various
inflammatory diseases, including atherosclerosis [19],
Crohn’s disease [20], rheumatoid arthritis [21], and
prostate cancer [22,23]. Studies on the association of
TLR4 SNPs with COPD showed that the Asp299Gly
(rs4986790) and Thr399Ile (rs4986791) polymorphisms
of TLR4 gene were strongly associated with Caucasian
patients [24-26]. However, these two functional SNPs
were absent in the Japanese population according to the
HapMap Project. At present, no TLR4 SNPs have yet
been reported with the emphysema phenotype of COPD
in Japanese subjects. In this case-control study, we
investigated the association between TLR4 SNPs and
COPD in Japanese subjects, with a focus on the emphy-
sema phenotype.
Results
Characteristics of study subjects
Table 1 shows the characteristics and spirometric data
of the study subjects. We selected 106 patients (102
males and 4 females) with the emphysema phenotype
from 268 patients with COPD and 137 controls (133
males and 4 females) from healthy smokers for health
screening in our afflicted hospitals. The gender ratio
was matched between the case and control groups (p =
0.711), however, the age and smoking history were sig-
nificantly higher in patients with emphysema compared
to controls (p < 0.001). The FEV1/FVC and %FEV1 were
significantly lower in patients with emphysema com-
pared to control smokers (p < 0.001). Table 2 shows the
information about the severity of the airflow limitation
determined by GOLD classification and the total LAA
score determined by Goddard’s method in the emphy-
sema group.
Genetic information of the study subjects
The genotypic distributions of all seven SNPs in control
smokers were in HWE (p > 0.2). The allelic positivities
of the examined SNPs in the TLR4 gene are shown in
Table 3. Compared to the control smokers, patients
with emphysema had significantly lower positivity for
the major G allele of rs11536889 (p = 0.019, odds ratio
(OR) = 0.38, 95% confidence interval (CI) = 0.17-0.86).
The other six SNPs did not show significant differences
Table 1 Study subject characteristics and baseline
spirometry data*
Emphysema Controls
Number of subjects 106 137
Male/Female 102/4 133/4
Age (years) 71.3 ± 6.8† 63.2 ± 10.0
Smoking history (pack-years) 63.3 ± 28.1† 39.6 ± 18.7
FEV1 (liter) 1.47 ± 0.66† 2.64 ± 0.51
FEV1 (% pred) 54.7 ± 22.8† 88.8 ± 13.1
FEV1/FVC (%) 48.4 ± 11.2† 80.3 ± 5.7
*Data are expressed as mean ± SD
Abbreviations: FEV1 forced expiratory volume in 1 second; % pred percent of
the predicted value; FVC forced vital capacity
†p < 0.001 versus controls by the Mann-Whitney U test
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3). Further analysis regarding the rs11536889 revealed
that the frequency of the minor C allele was significantly
higher in the patients with emphysema phenotype than
the health smokers (p = 0.0083), and the strength of the
association of the C allele with emphysema phenotype
was expressed by an OR of 1.69 with 95% CI from 1.14
to 2.50 (Table 4). Furthermore, the distribution of the
CC genotype was significantly frequent in the emphy-
sema group compared to that in the control group (p =
0.019), and the strength of the association of the CC
genotype with emphysema phenotype was in an OR of
2.60 with 95% CI from 17 to 5.78 (Table 4). Figure 1
shows the pair-wise LD of the seven SNPs in patients
with emphysema and control smokers. All SNP pairs
showed high LD values, ranging from 0.79 to 1.00 in the
cases and from 0.72 to 1.00 in control smokers. All SNP
pairs showed so strong LD values that the Bonferroni
method was not applied to adjust from multiple com-
parisons of the seven SNPs in order to avoid false nega-
tive results. The seven SNPs constituted a haplotype
block in the TLR4 gene in both groups. Table 5 shows
the nucleotide structures of the four most common hap-
lotypes that contained the seven TLR4 SNPs and the
observed frequencies in the two groups. The major hap-
lotype, TACGCAA (with the minor C allele of
rs11536889), occurred significantly more frequent in the
case group (0.336) than the control group (0.219, p =
0.004), with an OR of 1.8 (95% CI: 1.21-2.70). The
fourth most common haplotype, CGTTGAA (with the
major G allele of rs11536889), was observed more fre-
quently in the control smokers (0.165) than the patients
with emphysema (0.100, p = 0.039), with an OR of 0.56
(95% CI: 0.33-0.97).
In addition, the %FEV1, %DLco, and LAA scores did
not show any associations with the major or minor
alleles of the seven SNPs in patients with the emphy-
sema phenotype (data not shown).
Discussion
The present study showed the minor C allele and the
CC genotype of the rs11536889 SNP in the TLR4 gene
were likely associated with the emphysema phenotype of
COPD in Japanese subjects. The strength of the associa-
tion of the CC genotype with emphysema phenotype
w a si na nO Ro f2 . 6 0 .M o r e o v e r ,t h ef r e q u e n c yo ft h e
major haplotype (Haplotype 1), which carried the minor
Ca l l e l eo frs11536889, was significantly higher in the
Table 2 The severity of airflow limitation and total LAA
scores in patients with emphysema phenotype
GOLD stage * Number of patients (%)
Stage I 18 (17.0%)
Stage II 42 (39.6%)
Stage III 28 (26.4%)
Stage IV 18 (17.0%)
Total LAA score
† Patient number (%)
7-12 46 (43.4%)
13-18 24 (22.6%)
19-24 36 (34.0%)
Abbreviations: GOLD global initiative for chronic obstructive lung disease; LAA
low attenuation area
*determined by GOLD spirometric classification
†determined by Goddard’s method; scores represent total LAAs detected in 6
lung images
Table 3 Allelic positivities of single nucleotide
polymorphisms (SNPs) in the TLR4 gene in Japanese
subjects.
dbSNP* Location
Position
Allele Emphysema
(N = 106)
Controls
(N = 137)
O.R. P
Allelic Positivity
n (%)
rs10759930 promoter
119,501,442
T
C
92 (86.8)
62 (58.5)
111 (81.0)
83 (60.6)
1.54
0.92
0.229
0.741
rs1927914 promoter
119,504,546
A
G
92 (86.8)
62 (58.5)
111 (81.0)
83 (60.6)
1.54
0.92
0.229
0.741
rs12377632 intron 2
119,512,551
C
T
92 (86.8)
61 (57.5)
111 (81.0)
82 (59.9)
1.54
0.91
0.229
0.717
rs2149356 intron 2
119,514,020
G
T
93 (87.7)
61 (57.5)
111 (81.0)
82 (59.9)
1.68
0.91
0.157
0.717
rs11536889 3’UTR
119,517,952
G
C
88 (83.0)
58 (54.7)
127 (92.7)
58 (42.3)
0.38
1.65
0.019
rs7037117 3’UTR
119,523,484
A
G
102 (96.2)
44 (41.6)
133 (97.1)
51 (37.2)
0.77
1.20
0.711
0.497
rs7045953 3’UTR
119,525,616
A
G
106 (100)
18 (17.0)
137 (100)
21 (15.3)
-
1.13
-
0.728
Subjects included patients with emphysema and control smokers
*SNP designations are from the NCBI SNP database [29]. N = number of
subjects. n = number of present alleles
P values were calculated with c
2 tests of 2 × 2 contingency table
Table 4 Allelic frequency and genotypic distribution of
the rs11536889 in the TLR4 gene in emphysema and
control groups
rs11536889 Type Emphysema
(N = 106)
Controls
(N = 137)
O.R. PP
a
Allelic
frequency, n (%)
G 136(64.2) 206 (75.2) 0.59 0.0083
C 76 (35.8) 68 (24.8) 1.69*
Genotypic
distribution, n
(%)
GG 48 (45.3) 79 (57.7) 0.61 0.055
GC 40 (37.7) 48 (35.0) 1.12 0.664 0.034
CC 18 (17.0) 10 (7.3) 2.60
‡ 0.019
N number of subjects. n number of present alleles or genotypes
correspondingly
P and P
a values were calculated with c
2 tests of 2 × 2 and 3 × 2 contingency
tables, respectively
*Odds Ratio = 1.69, 95% Confidence Intervals = 1.14-2.50
‡Odds Ratio = 2.60, 95% Confidence Intervals = 1.17-5.78
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type (Haplotype 4), which carried the major G allele of
the rs11536889, was significantly higher in the in the
controls than the emphysema group. However, we
found that the clinical features of emphysema, such as
%FEV1, %DLco and LAA scores were not significantly
associated with the presence of rs11536889 in patients
with emphysema.
TLRs are expressed in many cells, including airway
epithelial cells, alveolar type II epithelial cells, alveolar
macrophages, endothelium, fibroblasts, vascular smooth
muscle cells, and T-cells [27]. TLR4s can recognize both
LPS and a respiratory syncytial virus fusion protein [28].
The latter is a major respiratory pathogen in humans,
infects the lower respiratory tract, and can exacerbate
COPD. TLR4 can also be activated by proteins released
from dead and dying cells, and tissue matrix breakdown
products in the absence of infection, including high-
mobility group protein 1 [29], surfactant protein A [30],
fibronectin [31], fibrinogen [32], and hyaluronic acid oli-
gosaccharides [33]. In smokers, stimulation with TLR4
agonists caused alveolar macrophages to reduce gene
expression and secrete proinflammatory cytokines and
chemokines [34]. Smokers and severe COPD patients
displayed reduced TLR4 gene expression in the nasal
epithelium. Consistent with that finding, a human
epithelial cell line exposed to cigarette smoke extracts
showed dose-dependent reductions in TLR4 mRNA and
protein expression [35]. Those findings suggested that
T L R 4m i g h tp l a yac r u c i a lr o l ei nt h ep a t h o g e n e s i so f
COPD inflammation.
In the present study, the distribution of the
rs11536889 CC genotype in control smokers was consis-
tent with that reported for Japanese subjects in the Hap-
Map project. In contrast, the CC genotype in the
emphysema group was significantly higher than in the
controls. The C allelic was also associated with emphy-
sema phenotype. The rs11536889 C allele was previously
demonstrated to be associated with moderate and severe
periodontitis [36] and a high risk of gastric atrophy in
Helicobacter pylori seropositive Japanese subjects [37].
However, the rs11536889 was not associated with auto-
immune pancreatitis [38] or sarcoidosis-related uveitis
[39] in Japanese subjects.
The rs11536889 SNP is located in the 3’-UTR of the
TLR4 gene on chromosome 9q32-q33; it substitutes the
ancestral guanine (G) with a mutated cytosine (C) at
nucleotide position 3725. This SNP does not have any
direct influence on the conformation of the TLR4 pro-
tein molecule, according to updated biogenetic data.
emphysema control smokers
Figure 1 Linkage disequilibrium (LD) plot of seven SNPs of the TLR4 gene. LD plots were prepared for subjects with emphysema (left) and
control smokers (right); D’_values that correspond to SNP pairs are expressed as percentages and shown within the respective squares. Higher D’
values are indicated with a brighter red color. These seven SNPs constitute a haplotype block that spans 24 kb of the TLR4 gene.
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may have an effect on mRNA stability and transcription
and/or translation efficiency; this might cause a dysfunc-
tion of the TLR4 molecule and interfere with the host
immune system.
Two mutations in the TLR4 gene, Asp299Gly
(rs4986790) and Thr399Ile (rs4986791), were reported
to be highly associated with COPD in Caucasians
[24-26], but these two functional SNPs were absent in
the Japanese population according to the HapMap Pro-
ject. At present, no other additional SNPs of the TLR4
gene have been reported to be associated with emphy-
sema or COPD in Japanese or other populations
worldwide.
The major limitation of the present case-control study
was the relatively small sample sizes for both the case
and control groups. The cases were strictly defined as
the emphysema phenotype among the COPD patients
by HRCT evaluation that was only applied to a part of
the COPD patients due to several reasons of the
patients. And the control group was recruited from the
health centers where the apparent healthy people,
mostly before retirement, voluntarily visit and take med-
ical check-up once a year. As a result, the age and
smoking history were significantly higher in the case
group than the control group. When we analyzed the
association of the rs11536889 SNPs with the emphysema
phenotype, logistic regression was performed to adjust
for age and smoking history as potential confounders.
However, the significances in comparisons of the allelic
frequency, genotype distribution and allele positivity of
the rs11536889 between the emphysema and control
smokers were not apparent. Logistic regression model
allows adjustment for confounders with a representative
random sample from the targeted study population
assuming without bias [40], but that tends to systemati-
cally overestimate odds ratios when the sample size is
less than about 500 [40]. Since our case group of
emphysema phenotype was selected from the COPD
population and the sample size was relatively small, we
don’t think logistic regression is suitable for the current
adjustments. The odds ratio of 1.69 with 95% CI from
1.14 to 2.50 regarding the minor C allele and the odds
ratio of 2.60 with 95% CI from 1.17 to 5.78 regarding
the CC genotype of the rs11536889 provided a positive
hint that the rs11536889 is important in the association
with emphysema phenotype. With increasing sample
size, the significances are supposed to approach the true
population values [40]. We would expect replication stu-
dies for the association of the rs11536889 with emphy-
sema in other Japanese groups. Further studies using
appropriate animal models may verify the roles of TLR4
rs11536889 polymorphism in the pathogenesis of
emphysema.
Conclusions
This study demonstrated that the rs11536889 (+3725 G/
C) SNP and the haplotype that carried the minor C
allele of this SNP in the TLR4 gene were likely asso-
ciated with the risk of developing the emphysema phe-
notype in the Japanese population.
Methods
Selection of cases
This study was approved by the Ethics Committee of
Shinshu University. We obtained written informed con-
sent from each case and control subject. Patients with
COPD were recruited from the Department of Respira-
tory Medicine in Shinshu University Hospital (Matsu-
moto, Japan), and all participants were Japanese. COPD
was diagnosed by smoking history, chronic respiratory
symptoms (cough, sputum, breathlessness), and spiro-
metric measurements that indicated an irreversible air-
flow limitation according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) [41]. Spiro-
metry and carbon monoxide diffusion capacity (DLco)
were measured with a pulmonary function testing sys-
tem (Chestac-55 V, Chest Co. Ltd., Tokyo, Japan).
Spirometry values were expressed as a percentage of the
predicted value for forced expiratory volume in 1 second
(%FEV1), which was based on equations formulated for
Japanese. An airflow limitation was defined as a ratio of
FEV1 to forced vital capacity (FVC) less than 70%
(FEV1/FVC < 70%). The severity of the airflow limitation
was determined according to spirometric classifications
of GOLD [41], as follows: all stages showed FEV1/FVC
Table 5 The four most common haplotypes were
comprised of the seven SNPs in the TLR4 gene.
SNPs Haplotypes*
1234
rs10759930 TT CC
rs1927914 AAGG
rs12377632 CCTT
rs2149356 GGTT
rs11536889 CG GG
rs7037117 AAGA
rs7045953 AAAA
Freq. in emphysema 0.336 0.301 0.142 0.100
Freq. in control smokers 0.219 0.386 0.123 0.165
p
†(emphysema vs. controls) 0.004
‡ 0.051 0.538 0.039
#
The observed frequencies are shown for patients with the emphysema
phenotype and control smokers
Abbreviations: A adenine; C cytosine; Freq. frequency; G guanine; SNPs single
nucleotide polymorphisms; T thymine; TLR4 Toll-like receptor 4
*The designation of haplotype structure is given in Arabic numerals
† By chi-square test
‡Odds Ratio = 1.80, 95% Confidence Intervals = 1.21- 2.70
# Odds Ratio = 0.56, 95% Confidence Intervals = 0.33- 0.97
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≤ %FEV1 < 80%; Stage III: 30% ≤ %FEV1 < 50%; and
Stage IV: %FEV1 < 30%.
Subjects with the following disorders were excluded
from the study: late sequelae of pulmonary tuberculosis,
diffuse panbronchiolitis, sinobronchitis, bronchiectasis,
bronchiolitis obliterans due to autoimmune disease, and
bronchial asthma.
The significant pathophysiological characteristic of
COPD is airflow limitation that is caused by mixture phe-
notypes of small airway disease (obstructive bronchiolitis)
and parenchymal destruction (emphysema), the relative
contributions of which vary from person to person [42].
As a result, most patients with COPD have a combina-
tion of both phenotypes. The cases in the current case-
control association study was strictly defined the patients
with emphysema phenotype which was identified by
high-resolution computed tomography (HRCT). A helical
CT scanner (Hi Speed Advantage, Light Speed Ultra 16,
or Light Speed VCT, GE Medical Systems, Milwaukee,
WI) was used for HRCT scanning at full inspiration
(total lung capacity level). We evaluated six slices, each
1.00-1.25 mm thick at three bilateral anatomic levels at
full inspiration: the upper lung field (near the superior
margin of the aortic arch), the middle lung field (at the
level of the carina), and the lower lung field (at the level
of the orifice of the inferior pulmonary veins). HRCT
images were acquired with a window setting appropriate
for the lungs (window level: -550 to -900 HU; width: 800
to 1500 HU). Low attenuation areas (LAA) were visually
evaluated in each bilateral lung field according to the
method of Goddard et al. [43] as follows: 0 = LAA < 5%;
1=5 %≤ LAA < 25%; 2 = 25% ≤ LAA < 50%; 3 = 50% ≤
LAA < 75%; 4 = 75% ≥ LAA. The total score was the sum
of the scores for six slices (maximum score = 24). We
defined the emphysema phenotype as a total score ≥ 7.
Selection of controls
Control smokers were recruited from a population that
underwent health screening at our affiliated hospitals
(Misayama Hospital and Shinmachi Hospital, Japan). Con-
trol smokers were selected based on normal spirometric
measurements. The selection criteria for controls were
Japanese ethnicity, 50 years old or more, and former or
current smoker. These criteria avoided ethnicity difference
in this case-control association study, minimized the gaps
of age and smoking history between the case and control
groups, as well as gained large enough sample size to
ensure statistical power for overcoming type I error.
Genotyping
DNA was extracted from whole blood with the Quick-
Gene-800 kit (FUJIFILM, Tokyo, Japan). Genomic DNA
was prepared at concentrations of 5-15 ng/μlf o rt h e
TaqMan SNP genotyping assay. Seven SNPs within the
TLR4 gene were genotyped, including rs10759930 and
rs1927914 in the 5’ untranslated region (UTR);
rs12377632,a n drs2149356 in intron 2; rs11536889,
rs7037117,a n drs7045953 in the 3’ UTR (Table 3).
These SNPs included 5 kb of the predicted 5’ UTR and
6 kb of the predicted 3’ UTR, with minor allele frequen-
cies > 5% according to the National Center for Biotech-
nology Information [44] SNP database. Genotyping the
SNPs was performed with the SNP Genotyping Kit
(Applied Biosystems, Tokyo, Japan). The polymerase
chain reaction (PCR) was performed with a TaqMan
Assay for Real-Time PCR (7500 Real Time PCR System;
Applied Biosystems) according to the manufacturer’s
instructions.
Statistical analysis
Continuous data are expressed as the mea n ± standard
deviation (SD). For continuous variables, the differences
between cases and controls were analyzed with the Mann-
Whitney U test. We also tested the Hardy-Weinberg equi-
librium (HWE) of each SNP among the controls. Allelic
positivity was expressed in percentage. The positivity was
defined as the frequency of individuals having one or two
of the identical alleles in a given group. Differences in
allele positivity between cases and controls were assessed
with the Chi-square test (2 × 2 contingency table). The
Haploview 3.32 program was used to compute pairwise
linkage disequilibrium (LD) statistics [45]. The D’ and r
2
values were plotted. LD blocks were defined according to
the criteria of Gabriel et al [46]. Comparisons of haplotype
frequencies between the cases and controls were per-
formed with the Chi-square test. Phenotype-genotype
associations were analyzed within the emphysema group
by comparing the severity of emphysema (total LAA
score), severity of airflow limitation (%FEV1), and dete-
rioration of gas exchange (%DLco = a percentage of the
predicted value for DLco) between patients with and those
without either the major or minor allele of a SNP. The
odds ratio (OR) and the approximate 95% confidence
interval (CI) were calculated. Statistical significance was
taken to be a p-value less than 0.05.
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